Sofwave Medical

Company Overview

Snapshot

Founded in October 2015 by Shimon Eckhouse, Ariel Sverdlik, and Genady Nahshon, Sofwave Medical operates with 51–200 employees. The company has raised $58.4M across two funding rounds and is publicly traded on TASE. In May 2021, Sofwave Medical completed its Initial Public Offering on the TASE, raising $50 million.

Business overview

Sofwave Medical specializes in non-invasive aesthetic medical solutions designed to improve skin laxity, provide lifting effects, and enhance muscle toning. The company utilizes its proprietary Synchronous Ultrasound Parallel Beam Technology (SUPERB™) to deliver controlled ultrasound energy to the mid-dermal layer, stimulating collagen and elastin production. Sofwave's product portfolio includes the Pure Impact add-on module, a plyometric muscle activation and toning device, which complements GLP-1 weight loss treatments by preventing muscle loss and increasing tone. Clinically validated and supported by multiple FDA clearances, Sofwave Medical serves the health tech and life sciences sectors, specifically targeting medical devices and aesthetic devices for healthcare providers and patients.

Strategic signal

In September 2025, Sofwave Medical received FDA pre-market clearance for its Pure Impact VIP™ Standalone EMS Device, designed for comprehensive multi-body area muscle strengthening and firming. This clearance signals a significant expansion of the company's product offerings beyond its core SUPERB™ technology, indicating a strategic move to address a broader range of aesthetic and wellness concerns, and potentially opening new market segments for investors.

Company Intelligence Q&A

What was a significant regulatory achievement for Sofwave Medical in September 2025?

In September 2025, Sofwave Medical received FDA pre-market clearance for its Pure Impact VIP™ Standalone EMS Device, which is designed for comprehensive multi-body area muscle strengthening and firming.

When did Sofwave Medical go public and what was the capital raised?

Sofwave Medical went public on the TASE in May 2021, raising $50 million through its Initial Public Offering.

What was a key patent granted to Sofwave in October 2024?

In October 2024, Sofwave obtained a U.S. Patent for its fat tissue reduction technology.

What award did Sofwave earn in November 2023?

In November 2023, Sofwave earned Frost & Sullivan's 2023 North American Technology Innovation Leadership Award for developing a sophisticated skin tightening ultrasound technology with minimal downtime.

When did Sofwave Medical gain approval to market its SUPERB™ device in Brazil?

In November 2022, Sofwave gained approval to market the SUPERB™ non-invasive wrinkle reduction device in Brazil.